ALX Oncology
Dr. Athanasios Tsiatis has served as the Senior Vice President, Clinical Development since November 2021. Prior to joining us, he was with Plexxikon Inc. from May 2018 to November 2021 where he served most recently as Vice President, Clinical Development from August 2020 to November 2021 and as Senior Director, Oncology Clinical Development from May 2018 to August 2020. Previously, Dr. Tsiatis held roles of increasing responsibility in clinical development at Genomic Health from 2011 to 2018. Dr. Tsiatis completed his postgraduate medical training at Vanderbilt University Medical Center, the Johns Hopkins Hospital, and the Hospital of the University of Pennsylvania. Dr. Tsiatis holds a B.A. in Biology from New York University and an M.D. from Vanderbilt University School of Medicine.
This person is not in any offices
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.